MBX Biosciences presents preliminary Phase 1 data for obesity candidate MBX 4291
MBX•MBX Biosciences reported mean weight loss of 7% at eight weeks in the first eight-person multiple-dose cohort of its ongoing, blinded Phase 1 trial, which included two placebo recipients. Twelve-week data are expected in the fourth quarter of 2026.
1. Early trial results
The ongoing, blinded Phase 1 trial recorded no serious adverse events; one participant experienced mild diarrhea, with no nausea or vomiting. MBX Biosciences also said its cash of $481.6 million is expected to fund operations into 2029.
